Research
Long-term remission and monocyclic course in Still’s disease patients starting canakinumab early: data from the international AIDA network registry
New evidence from the AIDA Network Still’s Disease Registry supports the benefits of early canakinumab treatment, showing higher rates of long-term remission, faster glucocorticoid reduction, and a greater likelihood of a monocyclic disease course.
Link to article
A new study based on data from the international AIDA Network Still’s Disease Registry has been published in Seminars in Arthritis and Rheumatism, providing encouraging evidence on the impact of early canakinumab initiation in patients with Still’s disease.
The analysis included 190 patients, comparing those who started canakinumab within 3 months from disease onset with those treated later. Patients receiving early treatment showed a more rapid reduction in glucocorticoid use, with decreases of 50% at month 3 and 75% at month 6, significantly greater than in patients treated later.
Most importantly, early canakinumab initiation was associated with a markedly higher probability of treatment discontinuation due to sustained long-term remission. In addition, a monocyclic disease course was observed in 49% of patients treated early, compared with only 8% of those starting therapy later, suggesting a substantial impact on the long-term evolution of the disease.
These findings reinforce the concept that timing matters in Still’s disease management and highlight once again the crucial role of the AIDA Network registries in generating international real-world evidence to improve patient care.